Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8771739 | MAYNE PHARMA INTL | Pharmaceutical compositions for poorly soluble drugs |
Jul, 2023
(5 months from now) | |
US10806792 | MAYNE PHARMA INTL | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(10 years from now) | |
US8921374 | MAYNE PHARMA INTL | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(10 years from now) | |
US10463740 | MAYNE PHARMA INTL | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(10 years from now) | |
US9272046 | MAYNE PHARMA INTL | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(10 years from now) | |
US9713642 | MAYNE PHARMA INTL | Itraconazole compositions and dosage forms, and methods of using the same |
Jun, 2033
(10 years from now) |
Drugs and Companies using ITRACONAZOLE ingredient
Market Authorisation Date: 11 December, 2018
Treatment: Treatment of fungal infections, including blastomycosis, histoplasmosis, and aspergillosis
Dosage: CAPSULE;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic